
Clinical UpdatesGLP-1 receptor agonisttype 2 diabetes
Cardiovascular Safety and Therapeutic Potential of Orforglipron Versus Insulin Glargine in Type 2 Diabetes with Elevated Cardiovascular Risk: Insights from the ACHIEVE-4 Phase 3 Trial
By MedXY|Oct 22, 2026
A comprehensive review of the ACHIEVE-4 trial confirms orforglipron’s cardiovascular safety non-inferior to insulin glargine in type 2 diabetes patients at elevated cardiovascular risk, highlighting its oral administration and safety
